Login to Your Account

Clinic Roundup

Tuesday, November 20, 2012
• Genentech Inc., of South San Francisco, a member of the Roche Group, reported results from the Phase III AVAglio study showing that Avastin (bevacizumab) in combination with radiation and temozolomide chemotherapy improved progression-free survival by 36 percent vs. radiation and temozolomide plus placebo (p > 0.0001) in patients with newly diagnosed glioblastoma.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription